Stockscreener 앱 받기
0.918
10.00%
-0.102
시간 외 거래:
.93
0.012
+1.31%
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors - marketscreener.com
Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors - TradingView
AIM ImmunoTech (AIM) CEO converts Series G preferred into 25,000 common shares - Stock Titan
AIM ImmunoTech (AIM) director converts Series G preferred into 25,000 shares - Stock Titan
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (AIM) director gets Series G preferred and 50,000 warrants - Stock Titan
AIM ImmunoTech (AIM) CEO details Series G preferred and 50,000 warrants - Stock Titan
AIM ImmunoTech Inc. Signs Dealer-Manager Agreement with Maxim Group LLC for Rights Offering – SEC Form 8-K Filing March 2026 - Minichart
AIM ImmunoTech Completes Series G Preferred Rights Offering - The Globe and Mail
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
AIM ImmunoTech Announces Closing of its Rights Offering - Caledonian Record
AIM ImmunoTech completes rights offering, creates new preferred stock series - Investing.com
AIM ImmunoTech Appoints Equiniti as Warrant Agent for $1.8 Million Rights Offering - TradingView
AIM ImmunoTech (NYSE: AIM) raises $1.8M, issues Series G preferred and warrants - Stock Titan
Advance Information Marketing Bhd. (AIM) - Minichart
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) Updates Rights Offering Terms - GuruFocus
AIM ImmunoTech Reminds Stockholders of March 3, 2026 - GlobeNewswire
AIM ImmunoTech (NYSE American: AIM) offers 12,000 Units and 24M warrants - Stock Titan
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - The Manila Times
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Extends Rights Offering Subscription Period - GuruFocus
AIM ImmunoTech Inc. recently announced that it will extend the exercise period for shareholder subscription rights in its previously announced stock offering plan. - Bitget
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - The Manila Times
Aim Immunotech Announces Extension Of Subscription Period - TradingView
AIM ImmunoTech Announces Extension of Subscription Period - GlobeNewswire
AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi - Indian Pharma Post
AIM ImmunoTech (AIM) Reports Progress in Pancreatic Cancer Study - GuruFocus
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Bitget
AIM ImmunoTech Announces Planned Milestones in the Ongoing - GlobeNewswire
New pancreatic cancer trial pairs AIM drug with AstraZeneca's Imfinzi - Stock Titan
AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer By Investing.com - Investing.com Canada
1.20%
0.06%
자본화:
|
볼륨(24시간):